Terms: = Ovarian cancer AND NTRK1, ENSG00000198400, 4914, P04629, TRK1, MTC, DKFZp781I14186, p140-TrkA, TRKA, TRK AND Prognosis
3 results:
1. Prognostic and Theranostic Biomarkers in ovarian Clear Cell Carcinoma.
Wiedemeyer K; Wang L; Kang EY; Liu S; Ou Y; Kelemen LE; Feil L; Anglesio MS; Glaze S; Ghatage P; Nelson GS; Köbel M
Int J Gynecol Pathol; 2022 Mar; 41(2):168-179. PubMed ID: 33770057
[TBL] [Abstract] [Full Text] [Related]
2. Clinical and genetic determinants of ovarian metastases from colorectal cancer.
Ganesh K; Shah RH; Vakiani E; Nash GM; Skottowe HP; Yaeger R; Cercek A; Lincoln A; Tran C; Segal NH; Reidy DL; Varghese A; Epstein AS; Sonoda Y; Chi D; Guillem J; Temple L; Paty P; Hechtman J; Shia J; Weiser M; Aguilar JG; Kemeny N; Berger MF; Saltz L; Stadler ZK
Cancer; 2017 Apr; 123(7):1134-1143. PubMed ID: 27875625
[TBL] [Abstract] [Full Text] [Related]
3. Altered expression and activation of the nerve growth factor receptors trka and p75 provide the first evidence of tumor progression to effusion in breast carcinoma.
Davidson B; Reich R; Lazarovici P; Ann Flørenes V; Nielsen S; Nesland JM
Breast Cancer Res Treat; 2004 Jan; 83(2):119-28. PubMed ID: 14997042
[TBL] [Abstract] [Full Text] [Related]
